MXPA01005543A - Formulacion de liberacion controlada que consta de gnrh-ii. - Google Patents
Formulacion de liberacion controlada que consta de gnrh-ii.Info
- Publication number
- MXPA01005543A MXPA01005543A MXPA01005543A MXPA01005543A MXPA01005543A MX PA01005543 A MXPA01005543 A MX PA01005543A MX PA01005543 A MXPA01005543 A MX PA01005543A MX PA01005543 A MXPA01005543 A MX PA01005543A MX PA01005543 A MXPA01005543 A MX PA01005543A
- Authority
- MX
- Mexico
- Prior art keywords
- gnrh
- controlled release
- release formulation
- formulation
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9826662A GB2344287A (en) | 1998-12-03 | 1998-12-03 | Controlled release pharmaceutical formulation |
PCT/GB1999/004045 WO2000032218A1 (en) | 1998-12-03 | 1999-12-02 | Controlled release formulation comprising gnrh-ii |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01005543A true MXPA01005543A (es) | 2003-07-14 |
Family
ID=10843631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA01005543A MXPA01005543A (es) | 1998-12-03 | 1999-12-02 | Formulacion de liberacion controlada que consta de gnrh-ii. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1140133A1 (es) |
JP (1) | JP2002531411A (es) |
KR (1) | KR20010089538A (es) |
CN (1) | CN1332635A (es) |
AU (1) | AU770676B2 (es) |
BR (1) | BR9915943A (es) |
CA (1) | CA2353798A1 (es) |
CZ (1) | CZ20011893A3 (es) |
EE (1) | EE200100293A (es) |
GB (1) | GB2344287A (es) |
HR (1) | HRP20010421A2 (es) |
HU (1) | HUP0104943A3 (es) |
IL (1) | IL143496A0 (es) |
MX (1) | MXPA01005543A (es) |
NO (1) | NO20012636L (es) |
NZ (1) | NZ511984A (es) |
PL (1) | PL348575A1 (es) |
RU (1) | RU2233170C2 (es) |
SK (1) | SK7552001A3 (es) |
TR (1) | TR200102273T2 (es) |
WO (1) | WO2000032218A1 (es) |
ZA (1) | ZA200104530B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8334258B2 (en) | 2005-07-26 | 2012-12-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin) | Method for induction and enhancement of apoptosis in tumor cells |
GB0616111D0 (en) | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
EP2411038B1 (en) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
US20120208762A1 (en) | 2009-10-27 | 2012-08-16 | The Board Of Trustees Of The University Of Illinois | Methods of Diagnosing Diastolic Dysfunction |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2011094337A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
DK2547359T3 (en) | 2010-03-15 | 2016-06-06 | The Board Of Trustees Of The Univ Of Illionis | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS |
EP2582719B1 (en) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
US20120004182A1 (en) | 2010-07-02 | 2012-01-05 | Carsten Gruendker | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells |
WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
PE20140724A1 (es) | 2011-06-22 | 2014-07-10 | Univ Indiana Res & Tech Corp | Coagonistas del receptor de glucagon/glp-1 |
US9415123B2 (en) | 2011-10-10 | 2016-08-16 | The Regents Of The University Of Michigan | Polymeric nanoparticles for ultrasound imaging and therapy |
KR20140097151A (ko) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
SG11201408347UA (en) | 2012-06-14 | 2015-01-29 | Ambrx Inc | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
WO2013192129A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
AU2014241743B2 (en) | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
WO2016123142A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
CN104789524A (zh) * | 2015-04-30 | 2015-07-22 | 四川大学 | 骨质疏松大鼠原代成骨细胞分离培养方法及应用 |
US20180201937A1 (en) | 2015-08-04 | 2018-07-19 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
CA3050811A1 (en) * | 2017-01-20 | 2018-07-26 | Immune System Regulation Holding Ab | Novel compounds (immunorhelins) |
WO2019006235A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
MX2020001328A (es) | 2017-08-03 | 2020-03-20 | Amgen Inc | Muteinas de interleucina 21 y metodos de tratamiento. |
UY37870A (es) | 2017-09-08 | 2019-03-29 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención |
SG11202002114RA (en) | 2017-09-18 | 2020-04-29 | Univ California | Claudin6 antibodies and methods of treating cancer |
JP2019122373A (ja) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗pd−1抗体及び治療方法 |
US20200085776A1 (en) | 2018-09-10 | 2020-03-19 | Cardax, Inc. | Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease |
CA3134055A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
US20220177583A1 (en) | 2019-03-20 | 2022-06-09 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
WO2020196946A1 (ko) * | 2019-03-26 | 2020-10-01 | 노벨파마 주식회사 | 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
EP3952841A1 (en) | 2019-04-09 | 2022-02-16 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
WO2020223177A1 (en) | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
EP3962945A1 (en) | 2019-04-30 | 2022-03-09 | Instituto de Medicina Molecular João Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
WO2020263793A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
US20220280561A1 (en) | 2019-08-30 | 2022-09-08 | Research Institute At Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associted with mitochondrial dysfunction |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
EP4281187A1 (en) | 2021-01-20 | 2023-11-29 | Bioentre LLC | Ctla4-binding proteins and methods of treating cancer |
WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
DE3414595A1 (de) * | 1984-04-18 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden |
US4540513A (en) * | 1984-09-25 | 1985-09-10 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Decapeptide having gonadotropin releasing activity |
US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
NZ240214A (en) * | 1990-10-16 | 1993-02-25 | Takeda Chemical Industries Ltd | Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs |
IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
AU3388597A (en) * | 1996-06-13 | 1998-01-07 | University Of Cape Town | Human type ii gonadotropin-releasing hormone receptor |
-
1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
-
1999
- 1999-12-02 IL IL14349699A patent/IL143496A0/xx unknown
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/hu unknown
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/xx unknown
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/ja active Pending
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/pt not_active IP Right Cessation
- 1999-12-02 EE EEP200100293A patent/EE200100293A/xx unknown
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/sk unknown
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Application Discontinuation
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/es unknown
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/ru not_active IP Right Cessation
- 1999-12-02 CN CN99815183A patent/CN1332635A/zh active Pending
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/ko not_active Application Discontinuation
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/cs unknown
- 1999-12-02 PL PL99348575A patent/PL348575A1/xx not_active Application Discontinuation
- 1999-12-02 NZ NZ511984A patent/NZ511984A/xx unknown
-
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/no not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown
- 2001-06-01 HR HR20010421A patent/HRP20010421A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20012636L (no) | 2001-07-12 |
BR9915943A (pt) | 2001-08-21 |
ZA200104530B (en) | 2002-06-04 |
CA2353798A1 (en) | 2000-06-08 |
GB9826662D0 (en) | 1999-01-27 |
CN1332635A (zh) | 2002-01-23 |
JP2002531411A (ja) | 2002-09-24 |
AU770676B2 (en) | 2004-02-26 |
HRP20010421A2 (en) | 2002-06-30 |
KR20010089538A (ko) | 2001-10-06 |
EE200100293A (et) | 2002-08-15 |
HUP0104943A2 (en) | 2002-06-29 |
HUP0104943A3 (en) | 2002-08-28 |
WO2000032218A1 (en) | 2000-06-08 |
NO20012636D0 (no) | 2001-05-29 |
IL143496A0 (en) | 2002-04-21 |
NZ511984A (en) | 2002-11-26 |
SK7552001A3 (en) | 2002-02-05 |
EP1140133A1 (en) | 2001-10-10 |
RU2233170C2 (ru) | 2004-07-27 |
PL348575A1 (en) | 2002-06-03 |
GB2344287A (en) | 2000-06-07 |
TR200102273T2 (tr) | 2001-12-21 |
AU1573200A (en) | 2000-06-19 |
CZ20011893A3 (cs) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA01005543A (es) | Formulacion de liberacion controlada que consta de gnrh-ii. | |
ZA200004956B (en) | Vaccine composition. | |
HK1040060A1 (en) | Sustained release ranolazine formulations. | |
SG93831A1 (en) | Polimeric controlled release compositions | |
HK1042653A1 (en) | External preparation. | |
GB9804013D0 (en) | Formulations | |
ZA200101762B (en) | Immediate release tablet. | |
ZA997174B (en) | Antiparasitic formulations. | |
ZA9810081B (en) | Extended release formulation. | |
EG24226A (en) | Formulation | |
SG72947A1 (en) | Controlled release compositions | |
GB9905898D0 (en) | Controlled-dose formulation | |
GB9902304D0 (en) | Formulation | |
ZA993473B (en) | Pellet formulations. | |
AUPP279698A0 (en) | Sustained release formulation | |
ZA200102716B (en) | Solid pesticidal formulation. | |
GB9927614D0 (en) | Sterliant formulation | |
GB9815001D0 (en) | Formulations | |
GB9815002D0 (en) | Formulations | |
HUP0105425A3 (en) | Suspo-emulsion formulation | |
ZA994697B (en) | Pharmaceutical formulation. | |
ZA99918B (en) | Pharmaceutical formulation. | |
GB9816563D0 (en) | Controlled release formulations | |
GB9902236D0 (en) | Formulation | |
ZA997229B (en) | Medicinal formulation. |